| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/31/2012 | US8105610 Method of making novel erythrovirus V9 VP2 capsid polypeptides |
| 01/31/2012 | US8105609 Administering a vaccine of a nucleic acid having a transcriiptional unit (TU) to direct a host cell to to biosynthesize the matrix and envelope (M and E) protein antigens; the TU comprises a prM signal sequence and ribosomal bindng sequence; carriers; encephalitis and yellow fever |
| 01/31/2012 | US8105608 Method of treatment using ligand-immunogen conjugates |
| 01/31/2012 | US8105607 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia |
| 01/31/2012 | US8105606 Chimeric proteins that induce effects directed against viruses |
| 01/31/2012 | US8105605 Allergen formulation |
| 01/31/2012 | US8105604 WT1 modified peptide |
| 01/31/2012 | US8105603 Polypeptides that bind APRIL |
| 01/31/2012 | US8105602 Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof |
| 01/31/2012 | US8105601 Compositions and methods for modulating an immune response |
| 01/31/2012 | US8105600 Method of inducing high-titer neutralizing antibody responses in a host by administering immune complexes comprising anti-HIV-1 Env antibodies and the HIV-1 Env |
| 01/31/2012 | US8105599 Administering a compound which binds to a C-type lectin on the surface of a dendritic cell, with the proviso that the C-type lectin is not the DEC-205 receptor |
| 01/31/2012 | US8105598 Human monoclonal antibodies that specifically bind IGF-II |
| 01/31/2012 | US8105597 Aβ binding molecules |
| 01/31/2012 | US8105596 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 01/31/2012 | US8105595 Methods of using neutralizing anti-TLR4/MD2 antibodies |
| 01/31/2012 | US8105594 Methods for amyloid removal using anti-amyloid antibodies |
| 01/31/2012 | US8105593 Anti-ADDL monoclonal antibody and use thereof |
| 01/31/2012 | US8105592 Immunoglobulin composition for delivery therapeutics to gastrointestinal system and treatment of infection |
| 01/31/2012 | US8105591 Methods of antagonizing signal transduction in dorsal root ganglion cells |
| 01/31/2012 | US8105590 Methods of treating inflammation in neuronal tissue |
| 01/31/2012 | US8105589 Use of DR3 antibodies in the treatment of inflammatory disease |
| 01/31/2012 | US8105588 Human monoclonal antibodies against interleukin 8 (IL-8) |
| 01/31/2012 | US8105587 Methods of treating arthritis using IL-1β binding molecules |
| 01/31/2012 | US8105582 Tumour vaccine comprising allogenic or xenogeneic tumour cells |
| 01/31/2012 | US8105579 Bacteriophage-containing therapeutic agents |
| 01/31/2012 | US8105578 Administering interferon-sensitivity, replication-competent clonal Rna virus to mammals |
| 01/31/2012 | US8105574 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| 01/31/2012 | US8105568 Vitamin receptor binding drug delivery conjugates |
| 01/31/2012 | CA2496897C Methods and compositions for modulating xbp-1 activity |
| 01/31/2012 | CA2443947C Recombinant p. vivax merozoite protein-1 p42 vaccine |
| 01/31/2012 | CA2432370C Attenuated flaviviral live vaccine comprising a capsid protein deletion |
| 01/31/2012 | CA2426490C Vaccine composition comprising an antigen and a peptide having adjuvant properties |
| 01/31/2012 | CA2393251C Eliciting hcv-specific antibodies |
| 01/31/2012 | CA2380216C Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 01/31/2012 | CA2226087C Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
| 01/31/2012 | CA2208790C Adjuvant for vaccines comprising a hydrophobic sulfolipid polysaccharide |
| 01/26/2012 | WO2012012759A2 Anti-tumor antigen antibodies and methods of use |
| 01/26/2012 | WO2012012695A2 A method for the treatment of obesity |
| 01/26/2012 | WO2012012600A2 Peptide compounds to regulate the complement system |
| 01/26/2012 | WO2012012531A2 Compositions and methods featuring il-6 and il-21 antagonists |
| 01/26/2012 | WO2012012520A1 Enhanced binding of pro-inflammatory cytokines by polysaccharide-antibody conjugates |
| 01/26/2012 | WO2012012388A2 Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy |
| 01/26/2012 | WO2012011992A2 Ricin vaccine and methods of making and using thereof |
| 01/26/2012 | WO2012011917A1 Administration of rifalazil to immunocompromised patients |
| 01/26/2012 | WO2012011876A1 Methods for identifying candidate cytotoxic antibody molecules |
| 01/26/2012 | WO2012011868A1 Influenza vaccine |
| 01/26/2012 | WO2012011731A2 Method for separating and identifying calgranulin a as a dementia marker from blood cells |
| 01/26/2012 | WO2012011621A1 Amyloid-beta clearance |
| 01/26/2012 | WO2012011381A1 Malaria vaccine |
| 01/26/2012 | WO2012011045A1 Parapoxvirus vectors |
| 01/26/2012 | WO2012010978A2 A method of treating alzheimer's disease |
| 01/26/2012 | WO2012010973A2 Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition |
| 01/26/2012 | WO2012010970A2 A method of treating attention deficit hyperactivity disorder |
| 01/26/2012 | WO2012010966A2 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders |
| 01/26/2012 | WO2012010799A1 Formulation of anti-cd20 antibodies |
| 01/26/2012 | WO2012010696A1 Methods for cancer management targeting co-029 |
| 01/26/2012 | WO2012010582A1 Anti-cxcr5 antibodies and methods of use |
| 01/26/2012 | WO2012010291A1 Diagnostic and therapeutic methods and compositions for metabolic disease |
| 01/26/2012 | WO2012010290A1 Diagnostic and therapeutic methods and compositions for metabolic disease |
| 01/26/2012 | WO2012009977A1 FULLY HUMAN TNFα-FAB ANTIBODY AND PEGYLATED ANTIBODY THEREOF |
| 01/26/2012 | WO2012009790A1 Cross-protective pathogen protection, methods and compositions thereof |
| 01/26/2012 | WO2012009760A1 Anti-il-23 heterodimer specific antibodies |
| 01/26/2012 | WO2011003557A8 A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent |
| 01/26/2012 | WO2010144140A8 Egfr and par2 regulation of intestinal permeability |
| 01/26/2012 | US20120023600 Compositions and methods of use for antibodies of dickkopf-1 |
| 01/26/2012 | US20120022236 Recombinant Anti-VLA4 Antibody Molecules |
| 01/26/2012 | US20120022006 B-lymphocyte stimulator binding polypeptides and methods based thereon |
| 01/26/2012 | US20120021056 Methods and Systems for Inducing Immunologic Tolerance to Non-Self Antigens |
| 01/26/2012 | US20120021055 Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
| 01/26/2012 | US20120021050 Nanoparticle formulated glycolipid antigens for immunotherapy |
| 01/26/2012 | US20120021043 Nucleic Acids Comprising formula (NuGlXmGnNv)a and Derivatives Thereof as Immunostimulating Agent/Adjuvant |
| 01/26/2012 | US20120021010 Antiplatelet agent and methods of using the same |
| 01/26/2012 | US20120021007 Nitric oxide furoxan derivative compounds endowed with antitumoral activity |
| 01/26/2012 | US20120021005 Mycoplasma gallisepticum formulation |
| 01/26/2012 | US20120021004 Medium and method of deriving and using a mutated bacteria strain |
| 01/26/2012 | US20120021003 Vaccine for protection against streptococcus suis bacteria of various serotypes |
| 01/26/2012 | US20120021002 Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
| 01/26/2012 | US20120021001 Marked bovine viral diarrhea virus vaccines |
| 01/26/2012 | US20120021000 HIV DNA Vaccine Methods of Use |
| 01/26/2012 | US20120020999 DNA Vaccine Compositions with HIV/SIV Gene Modifications |
| 01/26/2012 | US20120020998 Plasmacytoid dendritic cell line used in active or adoptive cell therapy |
| 01/26/2012 | US20120020997 Multi plasmid system for the production of influenza virus |
| 01/26/2012 | US20120020996 Vaccines against clostridium difficile and methods of use |
| 01/26/2012 | US20120020995 Parapoxvirus vectors |
| 01/26/2012 | US20120020994 Multivalent, drying resistant, evolution-based vaccines |
| 01/26/2012 | US20120020993 Vaccine |
| 01/26/2012 | US20120020992 Production of Biologically Active Proteins |
| 01/26/2012 | US20120020990 Isolated mammalian monocyte cell genes; related reagents |
| 01/26/2012 | US20120020989 Methods of treating colorectal cancer |
| 01/26/2012 | US20120020988 Antibodies specifically binding to human TSLPR and methods of use |
| 01/26/2012 | US20120020987 MHC-Less cells |
| 01/26/2012 | US20120020986 Antibodies to the PcrV Antigen of Pseudomonas aeruginosa |
| 01/26/2012 | US20120020985 Antibodies against il-17br |
| 01/26/2012 | US20120020984 Genetic Markers for Predicting Responsiveness to Combination Therapy |
| 01/26/2012 | US20120020983 Emp2 antibodies and their therapeutic uses |
| 01/26/2012 | US20120020982 Formulations and treatments for trichology |
| 01/26/2012 | US20120020981 Anti-IL6/IL-6R Antibodies and Methods of Use Thereof |
| 01/26/2012 | US20120020980 High affinity human antibodies to human cytomegalovirus (cmv) gb protein |
| 01/26/2012 | US20120020979 METHODS FOR TREATING IgE-MEDIATED DISORDER |